Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Vaginal MucoCept-CVN in Healthy Women
NCT07181486Phase 1Recruiting
- Start
- Oct 2025
- Primary completion
- Apr 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MucoCept in human immunodeficiency virus infection (HIV) (3 arms). Primary endpoints: Safety of MucoCept-CVN - Adverse Events at 8 weeks and Antibiotic Clearance of L.jensenii 1153-1666 at 8 weeks. Started Oct 2025; status: recruiting.
02
Drugs
MucoCept
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07181486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07181486.